Absci shares are trading higher after the company announced interim Phase 1 data from its first-in-human trial of ABS-201. The company priced its $100 million underwritten offering of 13,495,277 shares at $7.41.

Benzinga Newsdesk www.benzinga.com Positive 90.5%

Neg 0% Neu 0% Pos 90.5%

Comments

No comments yet. Be the first!